Information Journal Paper
APA:
Copy. (2021). Overview of the rationale for LGlutamine treatment in moderate-severe COVID-19 Infection. Journal of Infectious Diseases and Epidemiology, 7(-), 187-187. SID. https://sid.ir/paper/1078005/en
Vancouver:
Copy. Overview of the rationale for LGlutamine treatment in moderate-severe COVID-19 Infection. Journal of Infectious Diseases and Epidemiology[Internet]. 2021;7(-):187-187. Available from: https://sid.ir/paper/1078005/en
IEEE:
Copy, “Overview of the rationale for LGlutamine treatment in moderate-severe COVID-19 Infection,” Journal of Infectious Diseases and Epidemiology, vol. 7, no. -, pp. 187–187, 2021, [Online]. Available: https://sid.ir/paper/1078005/en